Company profile
Innovation1 Biotech Inc.
OTC: IVBT · Healthcare · Biotechnology
PublicHQ Somerville, NYCIK 0001629205Reports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 22GM —SS 18
v0.1 · 25/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ workforce scale, 3-yr revenue growth
Methodology →Revenue TTM
$104.9k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$6.0M
Employees
1
as of 2026-08-30
Market cap
$4.5k
as of 2026-08-30
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$6.0M-$6.0M2023
Operating income-$1.4M-$1.4M2023
Total assets$76.0k$76.0k2023
Liabilities$3.5M$3.5M2023
Equity-$3.4M-$3.4M2023
Revenue trend
FY2018 – FY2023 · USD
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Innovation1 Biotech Inc.’s revenue?
Innovation1 Biotech Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
PAO Group, Inc.——Arno Therapeutics, Inc.——Life Stem Genetics Inc.——ForU Holdings, Inc.——Xeno Transplants Corporation——Claritas Pharmaceuticals, Inc.——Key facts
CEOFrancis Knuettel
SectorHealthcare
IndustryBiotechnology
HeadquartersSomerville, NY
ExchangeOTC: IVBT
Employees1
IPO date2017-09-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.